Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion description "[The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion evidence source_evidence_literature NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion SIO_000772 23413279 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion wasDerivedFrom befree-20150227 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_assertion wasGeneratedBy ECO_0000203 NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.
- befree-20150227 importedOn "2015-02-27" NP341648.RAqpKQzmJHnBnFM2DH0MyqTuQfE0e3nwXgl2ow1dE2uf4130_provenance.